Gene Editing at the Cutting Edge of Molecular Medicine: Clinical, Ethical, and Biosafety Concerns in CRISPR Clinical Trials

Zoom Webinar

Watch Webinar On-Demand

About the Webinar

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology represents a revolutionary advancement in molecular medicine, offering unprecedented precision in gene editing. As its applications rapidly expand, from curing genetic disorders to pioneering new treatments, the importance of rigorous evaluation and oversight grows ever more critical.

Watch our insightful webinar on “Gene Editing at the Cutting Edge of Molecular Medicine: Clinical, Ethical, and Biosafety Concerns in CRISPR Clinical Trials,” hosted by WCG. This session delves into the latest developments in CRISPR-based therapies and the emerging guidelines from the National Institutes of Health (NIH) on how Institutional Biosafety Committees (IBCs) should assess these groundbreaking treatments.

Key Topics:

  • Clinical Advances: Explore the most recent breakthroughs in CRISPR clinical trials and their potential to transform healthcare.
  • Ethical Considerations: Understand the ethical implications of gene editing, including consent, equity, and the long-term impact on human genetics.
  • Biosafety Protocols: Gain insights into the new NIH guidelines for IBCs, emphasizing the importance of stringent biosafety measures to ensure the safe application of CRISPR technology.
  • Regulatory Landscape: Discuss the evolving regulatory framework and its impact on the development and deployment of CRISPR therapies.

Who Should Watch On-Demand:

  • Researchers and scientists in the field of genetics and molecular biology.
  • Healthcare professionals and clinical trial coordinators.
  • Members of Institutional Biosafety Committees (IBCs).
  • Bioethicists and regulatory affairs specialists.
  • Biotech and pharmaceutical industry stakeholders.

Don’t miss this opportunity to learn more about the increased biosafety oversight of CRISPR and gene editing clinical trials.